Trial · NCT05065905
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
NCT05065905, Phase 1, Phase 2, Completed, SPP Pharmaclon Ltd.; results first posted 2024-01-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis. Trials, record NCT05065905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05065905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
- NCT number
- NCT05065905
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 78 participants, actual
- Lead sponsor
- SPP Pharmaclon Ltd.
- Conditions
- HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus, Lentivirus Infections, RNA Virus Infections
- Interventions
- Interferon-Gamma
- First posted
- 2021-10-04
- Last updated
- 2024-01-25
- Results first posted
- 2024-01-25
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sputum Culture | Week 4 | Precentage of participants with negative sputum culture |
| Secondary | Average Hemoglobin Level | Screening, Week 8 | Level of hemoglobin (g/L) |
| Secondary | Leucocytes Level | Screening, Week 4 | Number of leukocytes |
| Secondary | CD3 | Screening, Week 4 | CD3 cells level in absolute numbers and percents |
| Secondary | CD4 | Screening, Week 4 | CD4 cells level in absolute numbers and percents |
| Secondary | CD8 | Screening, Week 4 | CD8 cells level in absolute numbers and percents |
| Secondary | CD4/CD8 | Screening, Week 4 | Immunoregulatory index value |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Sputum Culture | Week 4 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Average Hemoglobin Level | Screening, Week 8 | |||
| SECONDARY | Leucocytes Level | Screening, Week 4 | |||
| SECONDARY | CD3 | Screening, Week 4 | |||
| SECONDARY | CD4 | Screening, Week 4 | |||
| SECONDARY | CD8 | Screening, Week 4 | |||
| SECONDARY | CD4/CD8 | Screening, Week 4 |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Sputum Culture | Interferon | 15 | Participants | ||
| Sputum Culture | Interferon Daily | 20 | Participants | ||
| Sputum Culture | Control | 14 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Interferon | 30 | |
| Overall Study | STARTED | Interferon Daily | 28 | |
| Overall Study | STARTED | Control | 20 | |
| Overall Study | COMPLETED | Interferon | 30 | |
| Overall Study | COMPLETED | Interferon Daily | 28 | |
| Overall Study | COMPLETED | Control | 20 | |
| Overall Study | NOT COMPLETED | Interferon | 0 | |
| Overall Study | NOT COMPLETED | Interferon Daily | 0 | |
| Overall Study | NOT COMPLETED | Control | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Interferon | 0 | 30 |
| Total, all-cause mortality | Interferon Daily | 0 | 28 |
| Total, all-cause mortality | Control | 0 | 20 |
| Total, other adverse events | Interferon | 0 | 30 |
| Total, other adverse events | Interferon Daily | 0 | 28 |
| Total, other adverse events | Control | 0 | 20 |
| Total, serious adverse events | Interferon | 0 | 30 |
| Total, serious adverse events | Interferon Daily | 0 | 28 |
| Total, serious adverse events | Control | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05065905
GET https://conductscience.org/api/trials/v1/NCT05065905/registered